{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38527059", "DateCompleted": {"Year": "2024", "Month": "03", "Day": "27"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "27"}, "Article": {"Language": ["eng"], "ELocationID": ["e0011976", "10.1371/journal.pntd.0011976"], "ArticleDate": [{"Year": "2024", "Month": "03", "Day": "25"}], "Journal": {"ISSN": "1935-2735", "JournalIssue": {"Volume": "18", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Mar"}}, "Title": "PLoS neglected tropical diseases", "ISOAbbreviation": "PLoS Negl Trop Dis"}, "ArticleTitle": "Chitosan nanoparticles improve the effectivity of miltefosine against Acanthamoeba.", "Pagination": {"StartPage": "e0011976", "MedlinePgn": "e0011976"}, "Abstract": {"AbstractText": ["Acanthamoeba keratitis (AK) is a corneal sight-threatening infection caused by the free-living amoebae of the genus Acanthamoeba. Early and appropriate treatment significantly impacts visual outcomes. Mucoadhesive polymers such as chitosan are a potential strategy to prolong the residence time and bioavailability of the encapsulated drugs in the cornea. Regarding the recent administration of miltefosine (MF) for treating resistant AK, in the present study, we synthesized miltefosine-loaded chitosan nanoparticles (MF-CS-NPs) and evaluated them against Acanthamoeba.", "Chitosan nanoparticles (CNPs) were prepared using the ionic gelation method with negatively charged tripolyphosphate (TPP). The zeta-potential (ZP) and the particle size of MF-CS-NPs were 21.8\u00b13.2 mV and 46.61\u00b118.16 nm, respectively. The release profile of MF-CS-NPs indicated linearity with sustained drug release. The cytotoxicity of MF-CS-NPs on the Vero cell line was 2.67 and 1.64 times lower than free MF at 24 and 48 hours. This formulation exhibited no hemolytic activity in vitro and ocular irritation in rabbit eyes. The IC50 of MF-CS-NPs showed a significant reduction by 2.06 and 1.69-fold in trophozoites at 24 and 48 hours compared to free MF. Also, the MF-CS-NPs IC50 in the cysts form was slightly decreased by 1.26 and 1.21-fold at 24 and 48 hours compared to free MF.", "The MF-CS-NPs were more effective against the trophozoites and cysts than free MF. The nano-chitosan formulation was more effective on trophozoites than the cysts form. MF-CS-NPs reduced toxicity and improved the amoebicidal effect of MF. Nano-chitosan could be an ideal carrier that decreases the cytotoxicity of miltefosine. Further analysis in animal settings is needed to evaluate this nano-formulation for clinical ocular drug delivery."], "CopyrightInformation": "Copyright: \u00a9 2024 Latifi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Latifi", "ForeName": "Alireza", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Esmaeili", "ForeName": "Fariba", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Mohebali", "ForeName": "Mehdi", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran."}], "LastName": "Yasami-Khiabani", "ForeName": "Setayesh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Rezaeian", "ForeName": "Mostafa", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ocular Trauma and Emergency, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Soleimani", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": ["0000-0001-8634-5584"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Kazemirad", "ForeName": "Elham", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural products and medicinal plants Research center, North Khorasan University of Medical Sciences, Bojnurd, Iran."}], "LastName": "Amani", "ForeName": "Amir", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS Negl Trop Dis", "NlmUniqueID": "101291488", "ISSNLinking": "1935-2727"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drug Carriers"}, {"RegistryNumber": "9012-76-4", "NameOfSubstance": "Chitosan"}, {"RegistryNumber": "53EY29W7EC", "NameOfSubstance": "miltefosine"}, {"RegistryNumber": "107-73-3", "NameOfSubstance": "Phosphorylcholine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Rabbits"}, {"QualifierName": [], "DescriptorName": "Drug Carriers"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Chitosan"}, {"QualifierName": [], "DescriptorName": "Acanthamoeba"}, {"QualifierName": [], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["analogs & derivatives"], "DescriptorName": "Phosphorylcholine"}], "CoiStatement": "The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Szentm\u00e1ry N, Daas L, Shi L, Laurik KL, Lepper S, Milioti G, et al.. Acanthamoeba keratitis\u2013Clinical signs, differential diagnosis and treatment. J Curr Ophthalmol. 2019;31(1):16\u201323. doi: 10.1016/j.joco.2018.09.008", "ArticleIdList": ["10.1016/j.joco.2018.09.008", "PMC6407156", "30899841"]}, {"Citation": "Zhang Y, Xu X, Wei Z, Cao K, Zhang Z, Liang Q. The global epidemiology and clinical diagnosis of Acanthamoeba keratitis. J Infect Public Health. 2023;16(6):841\u2013852. doi: 10.1016/j.jiph.2023.03.020", "ArticleIdList": ["10.1016/j.jiph.2023.03.020", "37030037"]}, {"Citation": "Stellwagen A, MacGregor C, Kung R, Konstantopoulos A, Hossain P. Personal hygiene risk factors for contact lens-related microbial keratitis. BMJ Open Ophthalmol. 2020;5(1):e000476. doi: 10.1136/bmjophth-2020-000476", "ArticleIdList": ["10.1136/bmjophth-2020-000476", "PMC7481083", "32953996"]}, {"Citation": "Lorenzo-Morales J, Khan NA, Walochnik J. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite. 2015;22:10. doi: 10.1051/parasite/2015010 .", "ArticleIdList": ["10.1051/parasite/2015010", "PMC4330640", "25687209"]}, {"Citation": "Karsenti N, Lau R, Purssell A, Chong-Kit A, Cunanan M, Gasgas J, et al.. Development and validation of a real-time PCR assay for the detection of clinical acanthamoebae. BMC Res Notes. 2017;10(1):355. doi: 10.1186/s13104-017-2666-x", "ArticleIdList": ["10.1186/s13104-017-2666-x", "PMC5534048", "28754142"]}, {"Citation": "Juarez MM, Tartara LI, Cid AG, Real JP, Bermudez JM, Rajal VB, et al.. Acanthamoeba in the eye, can the parasite hide even more? Latest developments on the disease. Cont Lens Anterior Eye. 2018;41(3):245\u201351. doi: 10.1016/j.clae.2017.12.017", "ArticleIdList": ["10.1016/j.clae.2017.12.017", "29273391"]}, {"Citation": "Ti S-E, Scott JA, Janardhanan P, Tan DT. Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol. 2007;143(5):755\u201362. e2. doi: 10.1016/j.ajo.2007.01.015", "ArticleIdList": ["10.1016/j.ajo.2007.01.015", "17335767"]}, {"Citation": "Papa V, Rama P, Radford C, Minassian DC, Dart JK. Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol. 2020;104(4):575\u201381. doi: 10.1136/bjophthalmol-2019-314485", "ArticleIdList": ["10.1136/bjophthalmol-2019-314485", "31401556"]}, {"Citation": "Siddiqui R, Aqeel Y, Khan NA. The development of drugs against Acanthamoeba infections. Antimicrob Agents Chemother. 2016;60(11):6441\u201350. doi: 10.1128/AAC.00686-16", "ArticleIdList": ["10.1128/AAC.00686-16", "PMC5075048", "27600042"]}, {"Citation": "dos Santos Nogueira F, Avino VC, Galvis-Ovallos F, Pereira-Chioccola VL, Moreira MAB, Romariz APPL, et al.. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasit Vectors. 2019;12(1):1\u201311. doi: 10.1186/s13071-019-3323-0", "ArticleIdList": ["10.1186/s13071-019-3323-0", "PMC6368741", "30736866"]}, {"Citation": "Latifi A, Mohebali M, Yasami S, Soleimani M, Rezaian M, Kazemirad E. Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study. Acta Trop. 2023;247:107009. doi: 10.1016/j.actatropica.2023.107009", "ArticleIdList": ["10.1016/j.actatropica.2023.107009", "37643658"]}, {"Citation": "Bradley CS, Sicks LA, Pucker AD. Common ophthalmic preservatives in soft contact lens care products: benefits, complications, and a comparison to non-preserved solutions. Clin Optom (Auckl). 2021:271\u201385. doi: 10.2147/OPTO.S235679", "ArticleIdList": ["10.2147/OPTO.S235679", "PMC8434857", "34522149"]}, {"Citation": "Hirabayashi KE, Lin CC, Ta CN. Oral miltefosine for refractory Acanthamoeba keratitis. American Am J Ophthalmol Case Rep. 2019;16:100555. doi: 10.1016/j.ajoc.2019.100555", "ArticleIdList": ["10.1016/j.ajoc.2019.100555", "PMC6804782", "31650083"]}, {"Citation": "Macwan JS, Hirani A, Pathak Y. Challenges in ocular pharmacokinetics and drug delivery. Nano-biomaterials for ophthalmic drug delivery. 2016:593\u2013611. 10.1007/978-3-319-29346-2_26", "ArticleIdList": ["10.1007/978-3-319-29346-2_26"]}, {"Citation": "Gorantla S, Rapalli VK, Waghule T, Singh PP, Dubey SK, Saha RN, et al.. RSC Adv. 2020;10(46):27835\u201355. doi: 10.1039/d0ra04971a", "ArticleIdList": ["10.1039/d0ra04971a", "PMC9055630", "35516960"]}, {"Citation": "Begines B, Ortiz T, P\u00e9rez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F, et al.. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials (Basel). 2020;10(7):1403. doi: 10.3390/nano10071403", "ArticleIdList": ["10.3390/nano10071403", "PMC7408012", "32707641"]}, {"Citation": "Younes I, Rinaudo M. Chitin and chitosan preparation from marine sources. Structure, properties and applications. Mar Drugs. 2015;13(3):1133\u201374. doi: 10.3390/md13031133", "ArticleIdList": ["10.3390/md13031133", "PMC4377977", "25738328"]}, {"Citation": "Tripathi K, Singh A. Chitin, chitosan and their pharmacological activities: a review. Int J Pharm Sci Res. 2018;9(7):2626\u201335. 10.13040/IJPSR.0975-8232.9(7).2626-35", "ArticleIdList": ["10.13040/IJPSR.0975-8232.9(7).2626-35"]}, {"Citation": "Louisa M, Hawa P, Purwantyastuti P, Mardliyati E, Freisleben H-J. Primaquine-chitosan Nanoparticle Improves Drug Delivery to Liver Tissue in Rats. Open Access Maced. J. Med. Sci. 2022;10(A):1278\u201384. 10.3889/oamjms.2022.10005", "ArticleIdList": ["10.3889/oamjms.2022.10005"]}, {"Citation": "Riezk A, Van Bocxlaer K, Yardley V, Murdan S, Croft SL. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis. Molecules. 2020;25(17). doi: 10.3390/molecules25174002", "ArticleIdList": ["10.3390/molecules25174002", "PMC7504813", "32887341"]}, {"Citation": "Silva MM, Calado R, Marto J, Bettencourt A, Almeida AJ, Gon\u00e7alves LM. Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration. Mar Drugs. 2017;15(12):370. doi: 10.3390/md15120370", "ArticleIdList": ["10.3390/md15120370", "PMC5742830", "29194378"]}, {"Citation": "Zamboulis A, Nanaki S, Michailidou G, Koumentakou I, Lazaridou M, Ainali NM, et al.. Chitosan and its derivatives for ocular delivery formulations: Recent advances and developments. Polymers (Basel). 2020;12(7):1519. doi: 10.3390/polym12071519", "ArticleIdList": ["10.3390/polym12071519", "PMC7407599", "32650536"]}, {"Citation": "Tiyaboonchai W.\nChitosan nanoparticles: a promising system for drug delivery.\nJ. nat. sci.\n2013;11(3):51\u201366. https://www.journal.nu.ac.th/NUJST/article/view/250"}, {"Citation": "Dorlo TP, Eggelte TA, de Vries PJ, Beijnen JH. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst. 2012;137(5):1265\u201374. doi: 10.1039/c2an15641e", "ArticleIdList": ["10.1039/c2an15641e", "22251969"]}, {"Citation": "Sultan MH, Moni SS, Madkhali OA, Bakkari MA, Alshahrani S, Alqahtani SS, et al.. Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer. Sci Rep. 2022;12(1):468. doi: 10.1038/s41598-021-04427-w", "ArticleIdList": ["10.1038/s41598-021-04427-w", "PMC8748743", "35013493"]}, {"Citation": "Guideline I.\nStability testing of new drug substances and products. Q1A (R2), current step. 2003;4(1\u201324). https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-and-drug-products-scientific-guideline"}, {"Citation": "Jesus S, Marques AP, Duarte A, Soares E, Costa JP, Cola\u00e7o M, et al.. Chitosan nanoparticles: shedding light on immunotoxicity and hemocompatibility. Front Bioeng Biotechnol. 2020;8:100. doi: 10.3389/fbioe.2020.00100", "ArticleIdList": ["10.3389/fbioe.2020.00100", "PMC7047933", "32154232"]}, {"Citation": "Maciver SK, Asif M, Simmen MW, Lorenzo-Morales J. A systematic analysis of Acanthamoeba genotype frequency correlated with source and pathogenicity: T4 is confirmed as a pathogen-rich genotype. Eur J protistol. 2013;49(2):217\u201321. doi: 10.1016/j.ejop.2012.11.004", "ArticleIdList": ["10.1016/j.ejop.2012.11.004", "23290304"]}, {"Citation": "Soleimani M, Latifi A, Momenaei B, Tayebi F, Mohammadi SS, Ghahvehchian H. Management of refractory Acanthamoeba keratitis, two cases. Parasitol Res. 2021;120(3):1121\u20134. doi: 10.1007/s00436-020-06997-6", "ArticleIdList": ["10.1007/s00436-020-06997-6", "33409641"]}, {"Citation": "Walochnik J, Haller-Schober E-M, Kolli H, Picher O, Obwaller A, Aspock H. Discrimination between clinically relevant and nonrelevant Acanthamoeba strains isolated from contact lens-wearing keratitis patients in Austria. J Clin Microbiol. 2000;38(11):3932\u20136. doi: 10.1128/JCM.38.11.3932-3936.2000", "ArticleIdList": ["10.1128/JCM.38.11.3932-3936.2000", "PMC87520", "11060047"]}, {"Citation": "Walochnik J, Duch\u00eane M, Seifert K, Obwaller A, Hottkowitz T, Wiedermann G, et al.. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob Agents Chemother. 2002;46(3):695\u2013701. doi: 10.1128/AAC.46.3.695-701.2002", "ArticleIdList": ["10.1128/AAC.46.3.695-701.2002", "PMC127497", "11850250"]}, {"Citation": "Sangkanu S, Mitsuwan W, Mahabusarakam W, Jimoh TO, Wilairatana P, Girol AP, et al.. Anti-Acanthamoeba synergistic effect of chlorhexidine and Garcinia mangostana extract or \u03b1-mangostin against Acanthamoeba triangularis trophozoite and cyst forms. Sci Rep. 2021;11(1):8053. doi: 10.1038/s41598-021-87381-x", "ArticleIdList": ["10.1038/s41598-021-87381-x", "PMC8044166", "33850179"]}, {"Citation": "Khunkitti W, Avery S, Lloyd D, Furr J, Russell A. Effects of biocides on Acanthamoeba castellanii as measured by flow cytometry and plaque assay. J Antimicrob Chemother. 1997;40(2):227\u201333. doi: 10.1093/jac/40.2.227", "ArticleIdList": ["10.1093/jac/40.2.227", "9301988"]}, {"Citation": "Cooperation OfE Development. Test No. 405: Acute Eye Irritation/Corrosion: OECD Publishing; 2002. doi: 10.1787/9789264185333-en", "ArticleIdList": ["10.1787/9789264185333-en"]}, {"Citation": "Niza E, Nieto-Jim\u00e9nez C, Noblejas-L\u00f3pez MdM, Bravo I, Castro-Osma JA, de la Cruz-Mart\u00ednez F, et al.. Poly (cyclohexene phthalate) nanoparticles for controlled dasatinib delivery in breast cancer therapy. Nanomaterials (Basel). 2019;9(9):1208. doi: 10.3390/nano9091208", "ArticleIdList": ["10.3390/nano9091208", "PMC6780527", "31461998"]}, {"Citation": "Varacalli G, Di Zazzo A, Mori T, Dohlman TH, Spelta S, Coassin M, et al.. Challenges in Acanthamoeba Keratitis: A Review. J Clin Med. 2021;10(5). doi: 10.3390/jcm10050942", "ArticleIdList": ["10.3390/jcm10050942", "PMC7957573", "33804353"]}, {"Citation": "Mahdizadeh Barzoki Z, Emam-Djomeh Z, Rafiee-Tehrani M, Mortazavian E, Moosavi Movahedi AA. Optimization and development of insulin nanoparticles by new thiolated chitosan derivative with ionic gelation method using a model-based methodology. J Food Bioprocess Eng. 2019;2(1):25\u201334. https://jfabe.ut.ac.ir/article_73075.html"}, {"Citation": "Zhang C, Yin Y, Zhao J, Li Y, Wang Y, Zhang Z, et al.. An update on novel ocular nanosystems with possible benefits in the treatment of corneal neovascularization. Int J Nanomedicine. 2022:4911\u201331. doi: 10.2147/IJN.S375570", "ArticleIdList": ["10.2147/IJN.S375570", "PMC9578304", "36267540"]}, {"Citation": "Yi Qiaoli, Xu Zhijie, Thakur Abhimanyu, Zhang Kui, Liang Qiuju, Liu Yuanhong, Yan Yuanliang 2023:190:106733. doi: 10.1016/j.phrs.2023.106733", "ArticleIdList": ["10.1016/j.phrs.2023.106733", "36931541"]}, {"Citation": "Ibraheem DR, Hussein NN, Sulaiman GM, Mohammed HA, Khan RA, Al Rugaie O. Ciprofloxacin-Loaded Silver Nanoparticles as Potent Nano-Antibiotics against Resistant Pathogenic Bacteria. Nanomaterials (Basel). 2022;12(16). doi: 10.3390/nano12162808", "ArticleIdList": ["10.3390/nano12162808", "PMC9415342", "36014673"]}, {"Citation": "Alonso MJ, S\u00e1nchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2003;55(11):1451\u201363. doi: 10.1211/0022357022476", "ArticleIdList": ["10.1211/0022357022476", "14713355"]}, {"Citation": "Modaresi SMS, Ejtemaei Mehr S, Faramarzi MA, Esmaeilzadeh Gharehdaghi E, Azarnia M, Modarressi MH, et al.. Preparation and characterization of self-assembled chitosan nanoparticles for the sustained delivery of streptokinase: an in vivo study. Pharm Dev Technol. 2014;19(5):593\u20137. doi: 10.3109/10837450.2013.813542", "ArticleIdList": ["10.3109/10837450.2013.813542", "23859703"]}, {"Citation": "Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon. 2022;8(1):e08674. doi: 10.1016/j.heliyon.2021.e08674", "ArticleIdList": ["10.1016/j.heliyon.2021.e08674", "PMC8741465", "35028457"]}, {"Citation": "Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215\u201323. doi: 10.1016/j.yexmp.2008.12.004", "ArticleIdList": ["10.1016/j.yexmp.2008.12.004", "PMC3249419", "19186176"]}, {"Citation": "Kouchak M, Azarpanah A. Preparation and in vitro evaluation of chitosan nanoparticles containing diclofenac using the ion-gelation method. Jundishapur J Nat Pharm Prod. 2015;10(2). 10.17795/jjnpp-23082.", "ArticleIdList": ["10.17795/jjnpp-23082"]}, {"Citation": "Far J, Abdel-Haq M, Gruber M, Abu Ammar A. Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery. ACS omega. 2020;5(13):7432\u20139. doi: 10.1021/acsomega.0c00111", "ArticleIdList": ["10.1021/acsomega.0c00111", "PMC7144157", "32280885"]}, {"Citation": "Baharifar H, Khoobi M, Bidgoli SA, Amani A. Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme. Int J Biol Macromol. 2020;143:181\u20139. doi: 10.1016/j.ijbiomac.2019.11.157", "ArticleIdList": ["10.1016/j.ijbiomac.2019.11.157", "31758987"]}, {"Citation": "Li Z, Yang F, Yang R. Synthesis and characterization of chitosan derivatives with dual-antibacterial functional groups. Int J Biol Macromol. 2015;75:378\u201387. doi: 10.1016/j.ijbiomac.2015.01.056", "ArticleIdList": ["10.1016/j.ijbiomac.2015.01.056", "25666853"]}, {"Citation": "Narayan S. Lithium entrapped chitosan nanoparticles to reduce toxicity and increase cellular uptake of lithium. Environ Toxicol Pharmacol. 2018;61:79\u201386. doi: 10.1016/j.etap.2018.05.017", "ArticleIdList": ["10.1016/j.etap.2018.05.017", "29852373"]}, {"Citation": "Tripathi P, Jaiswal AK, Dube A, Mishra PR. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani. Int J Biol Macromol. 2017;105(Pt 1):625\u201337. doi: 10.1016/j.ijbiomac.2017.07.076", "ArticleIdList": ["10.1016/j.ijbiomac.2017.07.076", "28716750"]}, {"Citation": "Cabral FV, Pelegrino MT, Sauter IP, Seabra AB, Cortez M, Ribeiro MS. Nitric oxide-loaded chitosan nanoparticles as an innovative antileishmanial platform. Nitric oxide. 2019;93:25\u201333. doi: 10.1016/j.niox.2019.09.007", "ArticleIdList": ["10.1016/j.niox.2019.09.007", "31541732"]}, {"Citation": "Bashir SM, Ahmed Rather G, Patr\u00edcio A, Haq Z, Sheikh AA, Shah M, et al.. Chitosan Nanoparticles: A Versatile Platform for Biomedical Applications. Materials (Basel). 2022;15(19). doi: 10.3390/ma15196521", "ArticleIdList": ["10.3390/ma15196521", "PMC9570720", "36233864"]}, {"Citation": "Sorasitthiyanukarn FN, Muangnoi C, Gomez CB, Suksamrarn A, Rojsitthisak P, Rojsitthisak P. Potential Oral Anticancer Therapeutic Agents of Hexahydrocurcumin-Encapsulated Chitosan Nanoparticles against MDA-MB-231 Breast Cancer Cells. Pharmaceutics. 2023;15(2):472. doi: 10.3390/pharmaceutics15020472", "ArticleIdList": ["10.3390/pharmaceutics15020472", "PMC9959490", "36839794"]}, {"Citation": "Alli A, Ortiz JF, Morillo Cox \u00c1, Armas M, Orellana VA. Miltefosine: A Miracle Drug for Meningoencephalitis Caused by Free-Living Amoebas. Cureus. 2021;13(3):e13698. doi: 10.7759/cureus.13698", "ArticleIdList": ["10.7759/cureus.13698", "PMC8020194", "33833918"]}, {"Citation": "Jiang LQ, Wang TY, Webster TJ, Duan HJ, Qiu JY, Zhao ZM, et al.. Intracellular disposition of chitosan nanoparticles in macrophages: intracellular uptake, exocytosis, and intercellular transport. Int J Nanomedicine. 2017;12:6383\u201398. doi: 10.2147/IJN.S142060", "ArticleIdList": ["10.2147/IJN.S142060", "PMC5587219", "28919742"]}, {"Citation": "Jain V, Gupta A, Pawar VK, Asthana S, Jaiswal AK, Dube A, et al.. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014;174(4):1309\u201330. doi: 10.1007/s12010-014-1084-y", "ArticleIdList": ["10.1007/s12010-014-1084-y", "25106894"]}, {"Citation": "Vivek R, Babu VN, Thangam R, Subramanian K, Kannan S. pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells. Colloids Surf B Biointerfaces. 2013;111:117\u201323. doi: 10.1016/j.colsurfb.2013.05.018", "ArticleIdList": ["10.1016/j.colsurfb.2013.05.018", "23787278"]}, {"Citation": "Lakhundi S, Siddiqui R, Khan NA. Cellulose degradation: a therapeutic strategy in the improved treatment of Acanthamoeba infections. Parasit Vectors. 2015;8:1\u201316. doi: 10.1186/s13071-015-0642-7", "ArticleIdList": ["10.1186/s13071-015-0642-7", "PMC4300153", "25586209"]}, {"Citation": "Sharma G, Kalra SK, Tejan N, Ghoshal U. Nanoparticles based therapeutic efficacy against Acanthamoeba: Updates and future prospect. Exp Parasitol. 2020;218:108008. doi: 10.1016/j.exppara.2020.108008", "ArticleIdList": ["10.1016/j.exppara.2020.108008", "32979343"]}, {"Citation": "Chao M, Thongseesuksai T, Boonmars T, Laummaunwai P. Investigation of the in vitro cysticidal activity of miltefosine against Acanthamoeba spp. J Parasit Dis. 2020;44(2):491\u20135. doi: 10.1007/s12639-020-01204-w", "ArticleIdList": ["10.1007/s12639-020-01204-w", "PMC7244662", "32508430"]}, {"Citation": "Augustine R, Hasan A, Primavera R, Wilson RJ, Thakor AS, Kevadiya BD. Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components. Mater. Today Commun. 2020;25:101692. 10.1016/j.mtcomm.2020.101692.", "ArticleIdList": ["10.1016/j.mtcomm.2020.101692"]}, {"Citation": "Aibani N, Rai R, Patel P, Cuddihy G, Wasan EK. Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery. Pharmaceutics. 2021;13(10). doi: 10.3390/pharmaceutics13101686", "ArticleIdList": ["10.3390/pharmaceutics13101686", "PMC8540112", "34683979"]}, {"Citation": "Kalam MA. The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone. Int J Biol Macromol. 2016;89:559\u201368. doi: 10.1016/j.ijbiomac.2016.05.016", "ArticleIdList": ["10.1016/j.ijbiomac.2016.05.016", "27164496"]}, {"Citation": "Khan N, Khanna K, Bhatnagar A, Ahmad FJ, Ali A. Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: Statistical design, characterization and in vivo studies. Int J Biol Macromol. 2018;116:648\u201363. doi: 10.1016/j.ijbiomac.2018.04.122", "ArticleIdList": ["10.1016/j.ijbiomac.2018.04.122", "29723623"]}, {"Citation": "Bin-Jumah M, Gilani SJ, Jahangir MA, Zafar A, Alshehri S, Yasir M, et al.. Clarithromycin-loaded ocular chitosan nanoparticle: formulation, optimization, characterization, ocular irritation, and antimicrobial activity. Int J Nanomedicine. 2020:7861\u201375. doi: 10.2147/IJN.S269004", "ArticleIdList": ["10.2147/IJN.S269004", "PMC7568680", "33116505"]}]}], "History": [{"Year": "2023", "Month": "7", "Day": "29"}, {"Year": "2024", "Month": "2", "Day": "7"}, {"Year": "2024", "Month": "3", "Day": "27", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "3", "Day": "25", "Hour": "18", "Minute": "41"}, {"Year": "2024", "Month": "3", "Day": "25", "Hour": "13", "Minute": "35"}, {"Year": "2024", "Month": "3", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["38527059", "PMC10962830", "10.1371/journal.pntd.0011976", "PNTD-D-23-00965"]}}]}